Novartis ADR earnings missed by $0.02, revenue topped estimates
NeutralFinancial Markets

Novartis reported its ADR earnings, which fell short of expectations by $0.02, while its revenue exceeded estimates. This mixed performance highlights the challenges the company faces in meeting earnings targets, but the stronger revenue suggests that demand for its products remains robust. Investors will be keen to see how Novartis addresses these earnings shortfalls in future quarters.
— Curated by the World Pulse Now AI Editorial System









